SAVIENT CHAPTER 11 CASE INFORMATION
contact

 


home

OVERVIEW

 

Savient’s mission is to develop and commercialize pharmaceutical specialty products.  On September 14, 2010 the Food and Drug Administration (FDA) approved KRYSTEXXA® (pegloticase). 

We have exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University and Mountain View Pharmaceuticals, Inc.  Duke University developed the recombinant uricase enzyme and Mountain View developed the PEGylation technology used in the manufacture of KRYSTEXXA.  Mountain View and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.

Currently, we sell and distribute branded and generic versions of Oxandrin® (oxandrolone). We launched our authorized generic version of oxandrolone in December 2006.

   Pipeline

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

KRYSTEXXA®
(pegloticase)

Oxandrin®
(oxandrolone)

 
Partnerships

We have exclusively licensed worldwide rights to the technology related to KRYSTEXXA® (pegloticase) and its uses from Duke University and Mountain View Pharmaceuticals, Inc.  Duke University developed the recombinant uricase enzyme and Mountain View developed the PEGylation technology used in the manufacture of KRYSTEXXA.  Mountain View and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.

We depend on third parties to manufacture pegloticase and have entered into commercial supply agreements with third-party manufacturers.

Watson Pharma serves as the exclusive U.S. distributor of our authorized generic version of oxandrolone tablets, an Oxandrin® brand equivalent product that we supply to Watson Pharma.

This site is intended for U.S. audiences only.

 

     
     
 
For Chapter 11 Case Information relating to Savient Pharmaceuticals, Inc. and Savient Pharma Holdings, Inc Click Here